The research, conducted by a team at Shandong Second Medical University in Weifang, China, and published in BMC Medical Imaging, analyzed longitudinal tau-PET imaging data from participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Rather than treating tau as a single, uniform burden across the brain, the investigators asked a more granular question: which regions of tau accumulation carry the strongest warning about conversion from mild cognitive impairment (MCI) to full Alzheimer’s disease?

Tau is one of the two hallmark proteins of Alzheimer’s disease, the other being beta-amyloid. While amyloid plaques can accumulate for decades without obvious cognitive decline, tau—especially when it forms neurofibrillary tangles inside neurons—tracks much more closely with the actual death of brain cells and the erosion of memory and thinking abilities. Tau PET imaging, which uses radioactive tracers that bind to the pathological protein, allows researchers to visualize and quantify this burden in living patients rather than relying on autopsy data.

To identify the key regions, the team applied three complementary analytical methods to the imaging data: penalized generalized estimating equations (PGEE), which use a smoothly clipped absolute deviation penalty to screen variables while accounting for repeated measures in the same person; mixed-effects gradient boosting (MEGB); and mixed-effects random forest (MERF), two machine learning approaches that model longitudinal trajectories while capturing nonlinear relationships and individual variability. Only regions jointly identified by all three methods were carried forward, a deliberately conservative strategy designed to reduce the risk of false discoveries.

Six brain regions passed this triple filter: the entorhinal cortex, the amygdala, the inferior parietal cortex, the middle temporal gyrus, the parahippocampal gyrus, and the ventral posterior cingulate cortex. Many of these are familiar territory in Alzheimer’s research. The entorhinal cortex, a gateway structure connecting the hippocampus to the rest of the cortex, is typically the earliest site of tau accumulation and is central to memory function. The parahippocampal gyrus and amygdala, both parts of the medial temporal lobe’s memory circuitry, follow closely behind in the disease’s stereotypical spread pattern.

The researchers then constructed a multilevel joint model—a sophisticated statistical framework that simultaneously analyzes the longitudinal trajectory of tau deposition and the time-to-event process of conversion from MCI to Alzheimer’s disease. Joint models are powerful because they link the two processes, allowing the evolving tau measurements over repeated scans to directly inform the estimated risk of disease progression at each moment in time. This is a step beyond simpler approaches that rely on a single baseline scan, which can miss the dynamics of how tau evolves in individual patients.

The results revealed a striking hierarchy among the six regions. The entorhinal cortex showed the strongest association with progression risk, with a hazard ratio of 3.763 (95% confidence interval: 2.237–6.801), meaning that higher tau burden in this region roughly quadrupled the risk of converting to Alzheimer’s disease. The amygdala followed closely at a hazard ratio of 3.732 (95% CI: 2.326–6.164), and the inferior parietal cortex at 3.511 (95% CI: 2.109–6.013). The middle temporal gyrus (hazard ratio 2.770, 95% CI: 1.972–3.955) and the parahippocampal gyrus (hazard ratio 2.522, 95% CI: 1.833–3.529) also showed significant associations.

Notably, one region did not make the cut of meaningful predictors. The ventral posterior cingulate cortex, despite being jointly selected by all three screening methods, showed a hazard ratio of 1.354 with a confidence interval spanning 0.858 to 2.164—an interval that includes 1.0, indicating the association with progression risk was not statistically significant. This kind of heterogeneity across regions, the authors emphasize, is exactly why the multilevel joint modeling approach matters: tau in different brain areas is not equally informative about a patient’s future.

Perhaps the most clinically consequential finding concerns the timing of tau accumulation. When the researchers examined whether the rate of tau buildup—the trajectory or slope over repeated scans—or the current level of tau burden was the better predictor of progression, the answer was clear: current tau burden, rather than its accumulation rate, emerged as the dominant factor associated with the risk of conversion. In practical terms, where a patient’s tau levels stand right now matters more for predicting near-term progression than how fast those levels have been climbing.

This distinction has implications for how tau PET data might be used in clinical trials and, eventually, in clinical practice. Anti-amyloid therapies have recently received regulatory approval, but the field has long recognized that tau pathology is the stronger correlate of neuronal injury and cognitive decline. If the amount of tau in specific regions at a given visit is the most informative signal, then monitoring those regions could help identify MCI patients at highest risk who might benefit most from early intervention—and could serve as sensitive outcome measures in trials of tau-targeting therapies.

The study’s data came from the ADNI database, a widely used public resource that has followed hundreds of older adults with serial imaging, fluid biomarkers, and cognitive assessments. All participants provided written informed consent, and the analysis used de-identified data under the ADNI data use agreement. Using longitudinal tau-PET data—repeated scans from the same individuals over time—allowed the team to model within-person trajectories as well as between-person differences, a distinction captured by the mixed-effects and multilevel structure of their models.

The methodological pipeline itself represents a growing trend in Alzheimer’s research: combining classical biostatistics with machine learning to handle the high dimensionality of brain imaging. Tau PET scans yield standardized uptake value ratios (SUVRs) for dozens of distinct brain regions, and identifying which of these carry prognostic weight requires variable selection methods robust to correlation among regions and repeated measurements. The triangulation across PGEE, MEGB, and MERF gives the findings a level of robustness that any single method alone would not provide.

The work was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Shandong Province, and regional science and technology programs, and it is published open access. The authors, led by Yanxia Wang, Xinyu Yang, Yonghua Ma, and Aimin Wang as co-first authors, with Suzhen Wang and Fuyan Shi as corresponding authors, note that the study is citable under a permanent DOI while the final version of record is being completed.

For the field, the study adds a quantitative layer to a picture that has been forming for years: tau spreads through the brain along predictable pathways, and the specific regions it reaches—and how much of it settles there—encode information about how quickly a person will decline. By showing that the entorhinal cortex, amygdala, inferior parietal cortex, middle temporal gyrus, and parahippocampal gyrus each independently raise the risk of conversion from MCI to Alzheimer’s disease, and by quantifying that risk with region-specific hazard ratios, the study moves the field closer to a personalized, imaging-based prognostic tool.

That tool remains on the horizon rather than in the clinic. The findings are based on 126 participants, and hazard ratios from observational models describe associations, not certainty about any individual patient’s trajectory. Validation in independent cohorts, and integration with other biomarkers such as amyloid status and fluid markers of neurodegeneration, will be needed before tau PET in these five regions can guide individual clinical decisions. But as the search for effective Alzheimer’s treatments intensifies, knowing exactly where to look—and what level of tau in those places means for the road ahead—gives researchers and clinicians a sharper map of the disease’s most decisive early chapter.

Tau protein aggregation in the brain is a hallmark of Alzheimer’s pathology, second only to amyloid-beta accumulation. For decades, the scientific community has sought to ascertain how tau pathology correlates with the onset and progression of cognitive decline. Historically, amyloid-beta has been the focus of early AD biomarker discovery, but tau has increasingly gained prominence, partly due to its closer relation to neuronal damage and clinical symptoms. Using tau-specific PET ligands, clinicians and researchers can now visualize pathological tau deposits in vivo, providing an unprecedented window into disease mechanisms.

The multidisciplinary research team, led by Ossenkoppele et al., exploited an extensive cohort, encompassing individuals spanning a broad spectrum of cognitive states—from cognitively normal to various degrees of impairment. The participants underwent comprehensive neuroimaging and genotyping, allowing researchers to analyze several intersecting biological and demographic parameters. The core objective was to map the presence or absence of tau PET positivity, and understand how it interacts with normal aging, Aβ burden, genetic predisposition, and sex differences.

Age emerged as a dominant influence modulating tau accumulation, with positivity rates increasing substantially in older individuals. Yet, the researchers stress that tau deposition is far from a uniform process of aging: the interplay with amyloid-beta status creates a more nuanced landscape. Notably, tau PET positivity was significantly more prevalent among individuals with concomitant amyloid-beta pathology compared to those without, supporting the increasingly accepted hypothesis that amyloid-beta may create a permissive environment for tau spread throughout the cerebral cortex.

Moreover, the study illuminated the pivotal role of the apolipoprotein E (APOE) genotype, especially the ε4 allele, which is known as a major genetic risk factor for Alzheimer’s disease. Carriers of one or two ε4 alleles exhibited a higher probability of tau pathology even at younger ages and in the preclinical stages of disease. This finding highlights the potential of APOE genotyping as a stratification tool for identifying individuals at elevated risk for tauopathy, thereby enabling timely intervention strategies before cognitive symptoms manifest.

In addition to genetic and pathological factors, the researchers uncovered compelling evidence for sex-specific differences in tau accumulation. Women showed a distinct pattern of tau PET positivity compared to men, which may partly explain the higher incidence and prevalence of Alzheimer’s disease in females. These sex differences might be rooted in hormonal influences, differences in immune responses, or other molecular pathways yet to be fully elucidated, underscoring the critical necessity of incorporating sex as a biological variable in neurodegenerative disease research.

Methodologically, the use of advanced PET ligands that specifically bind paired helical filament tau ensures a highly sensitive and specific metric for disease staging. The imaging protocols integrated standardized uptake value ratios (SUVRs) obtained across multiple brain regions known to be involved in AD progression, such as the entorhinal cortex, hippocampus, and neocortex. Through sophisticated statistical modeling, including covariate adjustments for age, sex, APOE genotype, and amyloid status, the team was able to dissect complex interdependencies and isolate the individual contributions of each factor on tau pathology.

Importantly, the study also delves into the subset of cognitively unimpaired individuals who nevertheless display tau positivity on PET scans. This subgroup represents a critical window for early detection and possible therapeutic intervention, as tau accumulation could precede overt clinical symptoms by years or even decades. The ability to detect tau positivity prior to cognitive decline challenges previous paradigms and encourages a reevaluation of diagnostic criteria for preclinical Alzheimer’s disease.

Equally enlightening was the observation that tau PET positivity in amyloid-negative individuals was relatively rare and showed a different spatial topography compared to amyloid-positive cases. This suggests that tau deposition without concomitant amyloid-beta burden may signal alternative neurodegenerative pathologies or age-related tauopathies distinct from classical AD. Future longitudinal studies will be essential for unraveling these distinctions and understanding their prognostic implications.

The significance of combining genetic, molecular, imaging, and demographic data cannot be overstated. This multi-dimensional approach facilitates a precision medicine framework, wherein individuals can be categorized not only by clinical symptoms but also by their unique biological risk profiles. This specificity has clear ramifications for clinical trial design, enabling targeted enrollment and optimizing therapeutic outcomes by focusing on those most likely to benefit from tau-modulating interventions.

The findings also pose provocative questions about the mechanisms that drive sex-specific and APOE-modulated differences in tau pathology. For example, understanding whether these factors act synergistically or independently in promoting tau spread could unlock new therapeutic targets. Additionally, sex hormones might modulate tau phosphorylation or clearance pathways, suggesting that hormonal replacement therapies or modulators could influence disease trajectory.

From a translational perspective, the ability to identify tau positivity reliably in vivo promises to transform patient care. Clinicians might use tau PET imaging to personalize prognosis and stratify patients, choosing between available therapies or deciding on monitoring frequency. This is especially pertinent as emerging tau-targeting therapeutics enter clinical trials and require biomarkers to confirm target engagement and efficacy.

The study’s comprehensive dataset paves the way for further explorations into how environmental and lifestyle factors intersect with the identified biological variables. Understanding the modifiable risk component remains a priority, particularly as population aging continues globally and Alzheimer’s prevalence escalates.

Despite its strengths, the research team acknowledges limitations including the potential biases intrinsic to PET imaging sensitivity, the need for larger and more diverse cohorts, and the cross-sectional design, which can only infer but not prove causal relationships. Future longitudinal imaging studies, coupled with fluid biomarkers and cognitive assessments, will be paramount in charting the natural history of tau pathology across different populations.

In summary, Ossenkoppele et al.’s landmark study significantly advances our understanding of the interplay between tau pathology and critical biological factors in the aging brain. By highlighting how age, amyloid-beta status, APOE genotype, and sex shape the landscape of tau PET positivity, this research opens avenues for earlier diagnosis, better risk stratification, and the eventual realization of precision therapeutics in Alzheimer’s disease and related tauopathies. The convergence of genetics, imaging, and demographic science heralds a new frontier in neurodegenerative disease research, promising hope for millions at risk worldwide.

Subject of Research: Tau protein pathology as detected by PET imaging in relation to cognitive impairment, age, amyloid-beta status, APOE genotype, and sex differences.

Article Title: Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.

Article References:
Ossenkoppele, R., Coomans, E.M., Apostolova, L.G. et al. Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-02000-6

Image Credits: AI Generated